Reduction of Painful Oral Mucositis by Supersaturated Calcium Phosphate Oral Rinse in Head and Neck Cancer Patients Receiving Chemotherapy and Radiation

Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy: a review of current data

“…A broader range of patients were included in an observational study by Haas and co‐workers (2008a), which evaluated 218 cancer patients from an observational registry who received radiotherapy, chemotherapy or a combination of both, and were considered to be at high risk of developing OM. Patients in the registry had performed an oral rinse with Caphosol ® 4–10 times daily.…”

“…A sub‐analysis of the registry data, looking specifically at head and neck cancer patients (12% of whom received chemotherapy, 22% of whom received radiation therapy, and 66% of whom received combination therapy), also reported a low incidence and severity of OM: grade 0 or 1 OM was observed in 37–49% of patients; grade 2 in 33–39%; and grade 3 or 4 in 18–23% (Haas et al . 2008b).…”

“…The head and neck cancer subgroup analysis of Caphosol ® ‐treated patients in the Haas registry revealed that over 40% had grade 1 pain or lower, while grades 2 and 3 pain on the NCI‐CTC scale were experienced by 38% and 18% of patients, respectively; no grade 4 pain was reported (Haas et al . 2008b).…”

“…In the non‐comparative study of Caphosol ® by Haas et al . (2008a), 54% of patients required no pain medication, while opioids and non‐opioids (including NSAIDs) were used by 25% and 21% of patients respectively. The sub‐analysis of head and neck cancer patients from this study showed that opioid analgesia was required by 54% of patients at week 3 and 64% at week 8 of the study (Haas et al .…”

The use of MuGard™, Caphosol®and Episil®in patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck

“…Given the radiotherapy treatment volume in SCCHN, the majority of the oral mucosa will receive a significant dose of radiation; OM is realistically an inevitable toxicity rather than preventable consequence of head and neck radiotherapy. 9 Episil R is a lipid based oral spray that spreads onto the oral mucosa and transforms into a strongly bioadhesive 'fluid crystal' film that mechanically protects mucosa and aims to reduce the pain associated with OM. [5][6][7] Newer products: MuGard TM , Caphosol R and Episil R have been recently introduced.…”